DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kaletra (Lopinavir / Ritonavir) - Summary



(lopinavir/ritonavir) capsules
(lopinavir/ritonavir) oral solution

KALETRA (lopinavir/ritonavir) is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV protease. As co-formulated in KALETRA, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.

KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
See all Kaletra indications & dosage >>


Media Articles Related to Kaletra (Lopinavir / Ritonavir)

UNAIDS reports that reaching Fast-Track Targets will avert nearly 28 million new HIV infections
Source: HIV / AIDS News From Medical News Today [2014.11.21]
The Joint United Nations Programme on HIV/AIDS (UNAIDS) has announced that taking a Fast-Track approach over the next five years will allow the world to end the AIDS epidemic by 2030.

Practice-Changing Study in HIV-Related Lymphoma
Source: Medscape HIV/AIDS Headlines [2014.12.07]
Patients with HIV infection and lymphoma have been considered unsuitable for stem cell transplantation because of immunosuppression. A new study rewrites that script.
Medscape Medical News

In animal model, masking HIV target cells prevents viral transmission
Source: HIV / AIDS News From Medical News Today [2014.11.26]
Cloaking immune cells with antibodies that block T cell trafficking to the gut can substantially reduce the risk of viral transmission in a non-human primate model of HIV infection, scientists report.

Why HIV prevention dosing differs by sex
Source: Sexual Health / STDs News From Medical News Today [2014.11.03]
A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can...

more news >>

Published Studies Related to Kaletra (Lopinavir / Ritonavir)

Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. [2011.07]
The objective of this investigation was to evaluate the pharmacokinetic interaction of lopinavir/ritonavir (LPV/r) with BILR 355. In group A, 26 healthy participants were administered LPV/r (400mg/100mg) twice daily for 14 days, followed by coadministration of BILR 355, 150 mg twice daily for an additional 7 days...

Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression. [2011.06]
The purpose of this study was to determine if switching to an Lopinavir/ritonavir (LPV/r)-containing regimen resulted in greater immune reconstitution in patients with immunologic failure despite complete viral suppression with highly active antiretroviral therapy (HAART)... Switching patients to an LPV/r-containing regimen improved CD4(+) counts in patients with prior immunologic failure, and this may be due to an effect of LPV/r on apoptosis.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. [2011.02]
OBJECTIVES: To examine whether the overall results of the CASTLE study pertain to both genders, we analysed the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir in 277 female and 606 male patients in the open-label, multinational trial over 96 weeks. The trial is registered with ClinicalTrials.gov, number NCT00272779... CONCLUSIONS: Once-daily atazanavir/ritonavir is an effective and well-tolerated therapeutic option for women and men with HIV-1 infection. The sex-based differences in response may be due to higher discontinuation rates in women.

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. [2011.02]
S/GSK1349572 is an unboosted, once-daily integrase inhibitor with a novel resistance profile. As standard of care for patients infected with HIV is combination therapy, the potential interaction between S/GSK1349572 and ritonavir-boosted protease inhibitors was evaluated... The most frequent drug-related AEs were diarrhea, dizziness, and headache.

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial. [2011.01.01]
Given the decline in mortality among HIV-infected patients, it has become increasingly important to consider delayed disease-related and/or anti-HIV therapy-related adverse effects, such as lipodystrophy, when choosing initial therapy. Data from the MONARK trial allowed for comparison of the potential lipodystrophic effects of lopinavir/ritonavir (LPV/r) monotherapy with those of triple therapy with LPV/r plus zidovudine (ZDV) and lamivudine (3TC)...

more studies >>

Clinical Trials Related to Kaletra (Lopinavir / Ritonavir)

A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort [Completed]
The purpose of this study is to compare Kaletra tablets with Kaletra soft-gel capsules to see if there is any change in the side effects you may have and to see how people in the study feel about using the tablets.

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients [Completed]

Lopinavir Capsules to Kaletra or Invirase Tablets [Recruiting]
This study will compare the benefit for patients switching from Kaletra« to Invirase« tablets over remaining on Kaletra« (based on randomization), to elicit the lipid benefits inferred in previous studies

Kaletra: Therapy With Double Protease Inhibitors [Recruiting]
Therapy with Kaletra and one other protease inhibitor in Human Immunodeficiency Virus-patients

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients [Terminated]
To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

more trials >>

Reports of Suspected Kaletra (Lopinavir / Ritonavir) Side Effects

Foetal Exposure During Pregnancy (238)Maternal Exposure During Pregnancy (134)Premature Baby (90)Stillbirth (61)Abortion Spontaneous (60)Anaemia (49)Diarrhoea (38)Pyrexia (36)Death (36)Atrial Septal Defect (34)more >>

Page last updated: 2014-12-07

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014